NCT06256328 2026-03-13A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Ono Pharmaceutical Co. LtdPhase 2 Active not recruiting226 enrolled
NCT06109779 2026-03-04Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)AstraZenecaPhase 3 Active not recruiting757 enrolled
NCT05867121 2026-02-02A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010Genentech, Inc.Phase 1 Active not recruiting102 enrolled
NCT06693128 2026-01-28Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric CancerRuijin HospitalPhase 2 Active not recruiting80 enrolled
NCT04208347 2026-01-23Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerRuijin HospitalPhase 2/3 Active not recruiting580 enrolled
NCT05026905 2026-01-20A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic CancerNational Health Research Institutes, TaiwanPhase 2 Active not recruiting66 enrolled